PDCD1 and neoplasm: The combination of anti-angiogenic drugs with PD-1/PD-L1 inhibitors is synergistic as it can not only attenuate tumor-induced immunosuppression but also promote antitumor immunity and normalization of tumor blood vessels (Fukumura et al., 2018; Hack et al., 2020).